Yahoo Finance

JonesResearch lowered the firm’s price target on Lantheus (LNTH) to $120 from $134 and keeps a Buy rating on the shares following the Q1 report. With Pylarify facing competitive pressure and its net sales down 0.5% year-over- year, an ongoing business reorganization and reduced fiscal 2025 earnings guidance, the stock has faced significant negative pressure, the analyst tells investors in a research note. The firm acknowledges near-term concerns over emerging PSMA-PET competition and potential increased operating expenses arising from recent acquisitions, but continues to have confidence in the medium- to long-term potential of Lantheus’ radiopharmaceutical pipeline. It expects strong execution and improved margins following the completion of acquisitions and divestitures.

Protect Your Portfolio Against Market Uncertainty

• Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.

• Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on LNTH:

Disclaimer & DisclosureReport an Issue

• Lantheus: Strategic Growth Potential and Market Positioning Justify Buy Rating Despite Challenges

• Lantheus Holdings Reports Q1 2025 Financial Results

• Lantheus Holdings Earnings Call: Mixed Outlook Amid Strategic Moves

• Balancing Challenges and Opportunities: Justin Walsh’s Optimistic Buy Rating for Lantheus Holdings Amidst Strategic Reorganization

• Strategic Growth and Focus: Lantheus’s Positive Long-Term Outlook Justifies Buy Rating